ABCB1-mediated docetaxel resistance reversed by erastin in prostate cancer

Docetaxel (Doc) currently serves as the primary first-line treatment for patients with castrate-resistant prostate Cancer (CRPC). Erastin, a small molecule compound, can trigger inhibition of the cystine-glutamate reverse transport system and other pathways, leading to iron-dependent cell death (Ferroptosis). Beyond its role in inducing Cancer cell death, erastin demonstrates potential when combined with chemotherapy drugs to heighten Cancer cell drug susceptibility. However, the augmentation by erastin of the effects of Doc treatment on prostate Cancer, and the underlying mechanisms involved, remain unclear. In the present study, we determined the role and the underlying molecular mechanism of erastin against CRPC. The results showed that CRPC cell lines were resistant to Doc, and the expression of ferroptosis-related factors in drug-resistant cell lines was downregulated. Erastin, in synergy with Doc, exerts a pro-apoptotic effect. Erastin significantly inhibited the activity of ATP-binding cassette subfamily B member 1 (ABCB1) but did not change its protein expression and localization. Finally, in mice, erastin treatment dramatically reduced tumor growth in vivo. Taken together, our findings demonstrate that erastin enhances Doc-induced Apoptosis to a certain extent and reverses Doc resistance in prostate Cancer by inhibiting the activity of multidrug-resistant protein ABCB1.

ABCB1; docetaxel; erastin; prostate cancer.